Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats

Ming Hung Shih, Sheng Chin Kao, Wei Wang, Myron Yaster, Yuan Xiang Tao

Research output: Contribution to journalArticle

Abstract

Mammalian target of rapamycin (mTOR) controls mRNA translation and is critical for neuronal plasticity. However, how it participates in central sensitization underlying chronic pain is unclear. Here, we show that NMDA receptors are required for the functional role of spinal cord mTOR in bone cancer pain induced by injecting prostate cancer cells (PCCs) into the tibia. Intrathecal rapamycin, a specific mTOR inhibitor, dose dependently attenuated the development and maintenance of PCC-induced mechanical allodynia and thermal hyperalgesia. Rapamycin alone did not affect locomotor activity and acute responses to thermal or mechanical stimuli. Phosphorylation of mTOR and p70S6K (a downstream effector) was increased time dependently in L4-5 dorsal horn and transiently in L4-5 dorsal root ganglions on the ipsilateral side after PCC injection, although total expression of mTOR or p70S6K was not changed in these regions. The increases in dorsal horn were abolished by intrathecal infusion of DL-AP5, an NMDA receptor antagonist. Moreover, NMDA receptor subunit NR1 colocalized with mTOR and p70S6K in dorsal horn neurons. These findings suggest that PCC-induced dorsal horn activation of the mTOR pathway participates in NMDA receptor-triggered dorsal central sensitization under cancer pain conditions. Perspective: The present study shows that inhibition of spinal mTOR blocks cancer-related pain without affecting acute pain and locomotor function. Given that mTOR inhibitors are FDA-approved drugs, mTOR in spinal cord may represent a potential new target for preventing and/or treating cancer-related pain.

Original languageEnglish (US)
Pages (from-to)338-349
Number of pages12
JournalJournal of Pain
Volume13
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Bone Neoplasms
Sirolimus
N-Methyl-D-Aspartate Receptors
Spinal Cord
Hypersensitivity
Maintenance
70-kDa Ribosomal Protein S6 Kinases
Hyperalgesia
Prostatic Neoplasms
Central Nervous System Sensitization
Posterior Horn Cells
Cancer Pain
Neuronal Plasticity
Acute Pain
Spinal Ganglia
Protein Biosynthesis
Locomotion
Tibia
Chronic Pain
Hot Temperature

Keywords

  • activation
  • cancer pain
  • dorsal horn
  • mTOR
  • NMDA receptors

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats. / Shih, Ming Hung; Kao, Sheng Chin; Wang, Wei; Yaster, Myron; Tao, Yuan Xiang.

In: Journal of Pain, Vol. 13, No. 4, 04.2012, p. 338-349.

Research output: Contribution to journalArticle

@article{88b143fb9aad474cabba0b85521ef14b,
title = "Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats",
abstract = "Mammalian target of rapamycin (mTOR) controls mRNA translation and is critical for neuronal plasticity. However, how it participates in central sensitization underlying chronic pain is unclear. Here, we show that NMDA receptors are required for the functional role of spinal cord mTOR in bone cancer pain induced by injecting prostate cancer cells (PCCs) into the tibia. Intrathecal rapamycin, a specific mTOR inhibitor, dose dependently attenuated the development and maintenance of PCC-induced mechanical allodynia and thermal hyperalgesia. Rapamycin alone did not affect locomotor activity and acute responses to thermal or mechanical stimuli. Phosphorylation of mTOR and p70S6K (a downstream effector) was increased time dependently in L4-5 dorsal horn and transiently in L4-5 dorsal root ganglions on the ipsilateral side after PCC injection, although total expression of mTOR or p70S6K was not changed in these regions. The increases in dorsal horn were abolished by intrathecal infusion of DL-AP5, an NMDA receptor antagonist. Moreover, NMDA receptor subunit NR1 colocalized with mTOR and p70S6K in dorsal horn neurons. These findings suggest that PCC-induced dorsal horn activation of the mTOR pathway participates in NMDA receptor-triggered dorsal central sensitization under cancer pain conditions. Perspective: The present study shows that inhibition of spinal mTOR blocks cancer-related pain without affecting acute pain and locomotor function. Given that mTOR inhibitors are FDA-approved drugs, mTOR in spinal cord may represent a potential new target for preventing and/or treating cancer-related pain.",
keywords = "activation, cancer pain, dorsal horn, mTOR, NMDA receptors",
author = "Shih, {Ming Hung} and Kao, {Sheng Chin} and Wei Wang and Myron Yaster and Tao, {Yuan Xiang}",
year = "2012",
month = "4",
doi = "10.1016/j.jpain.2011.12.006",
language = "English (US)",
volume = "13",
pages = "338--349",
journal = "Journal of Pain",
issn = "1526-5900",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats

AU - Shih, Ming Hung

AU - Kao, Sheng Chin

AU - Wang, Wei

AU - Yaster, Myron

AU - Tao, Yuan Xiang

PY - 2012/4

Y1 - 2012/4

N2 - Mammalian target of rapamycin (mTOR) controls mRNA translation and is critical for neuronal plasticity. However, how it participates in central sensitization underlying chronic pain is unclear. Here, we show that NMDA receptors are required for the functional role of spinal cord mTOR in bone cancer pain induced by injecting prostate cancer cells (PCCs) into the tibia. Intrathecal rapamycin, a specific mTOR inhibitor, dose dependently attenuated the development and maintenance of PCC-induced mechanical allodynia and thermal hyperalgesia. Rapamycin alone did not affect locomotor activity and acute responses to thermal or mechanical stimuli. Phosphorylation of mTOR and p70S6K (a downstream effector) was increased time dependently in L4-5 dorsal horn and transiently in L4-5 dorsal root ganglions on the ipsilateral side after PCC injection, although total expression of mTOR or p70S6K was not changed in these regions. The increases in dorsal horn were abolished by intrathecal infusion of DL-AP5, an NMDA receptor antagonist. Moreover, NMDA receptor subunit NR1 colocalized with mTOR and p70S6K in dorsal horn neurons. These findings suggest that PCC-induced dorsal horn activation of the mTOR pathway participates in NMDA receptor-triggered dorsal central sensitization under cancer pain conditions. Perspective: The present study shows that inhibition of spinal mTOR blocks cancer-related pain without affecting acute pain and locomotor function. Given that mTOR inhibitors are FDA-approved drugs, mTOR in spinal cord may represent a potential new target for preventing and/or treating cancer-related pain.

AB - Mammalian target of rapamycin (mTOR) controls mRNA translation and is critical for neuronal plasticity. However, how it participates in central sensitization underlying chronic pain is unclear. Here, we show that NMDA receptors are required for the functional role of spinal cord mTOR in bone cancer pain induced by injecting prostate cancer cells (PCCs) into the tibia. Intrathecal rapamycin, a specific mTOR inhibitor, dose dependently attenuated the development and maintenance of PCC-induced mechanical allodynia and thermal hyperalgesia. Rapamycin alone did not affect locomotor activity and acute responses to thermal or mechanical stimuli. Phosphorylation of mTOR and p70S6K (a downstream effector) was increased time dependently in L4-5 dorsal horn and transiently in L4-5 dorsal root ganglions on the ipsilateral side after PCC injection, although total expression of mTOR or p70S6K was not changed in these regions. The increases in dorsal horn were abolished by intrathecal infusion of DL-AP5, an NMDA receptor antagonist. Moreover, NMDA receptor subunit NR1 colocalized with mTOR and p70S6K in dorsal horn neurons. These findings suggest that PCC-induced dorsal horn activation of the mTOR pathway participates in NMDA receptor-triggered dorsal central sensitization under cancer pain conditions. Perspective: The present study shows that inhibition of spinal mTOR blocks cancer-related pain without affecting acute pain and locomotor function. Given that mTOR inhibitors are FDA-approved drugs, mTOR in spinal cord may represent a potential new target for preventing and/or treating cancer-related pain.

KW - activation

KW - cancer pain

KW - dorsal horn

KW - mTOR

KW - NMDA receptors

UR - http://www.scopus.com/inward/record.url?scp=84862785387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862785387&partnerID=8YFLogxK

U2 - 10.1016/j.jpain.2011.12.006

DO - 10.1016/j.jpain.2011.12.006

M3 - Article

VL - 13

SP - 338

EP - 349

JO - Journal of Pain

JF - Journal of Pain

SN - 1526-5900

IS - 4

ER -